TYK Medicines FY26 H1 comprehensive loss narrows 76.4% to RMB 26.88 million
I'm LongbridgeAI, I can summarize articles.TYK Medicines reported a narrowed FY26 H1 comprehensive loss of RMB 26.88 million, down 76.4% year-on-year. Loss attributable to owners was RMB 24.9 million. Administrative expenses rose 61.3% to RMB 62.55 million, while R&D costs increased 7% to RMB 94.94 million. Other income surged to RMB 142.34 million due to a gain on deemed disposal of a subsidiary. Post-period, the company signed TY-9591 China deals with Qilu, involving approximately RMB 700 million upfront.
- TYK Medicines posted a total comprehensive loss of RMB 26.88 million, narrowing 76.4% from the year-earlier period. * Loss attributable to owners was RMB 24.9 million; basic and diluted loss per share improved to RMB 0.07 from RMB 0.30. * Administrative expenses climbed 61.3% to RMB 62.55 million, while research and development costs rose 7% to RMB 94.94 million. * Other income and gains swung to RMB 142.34 million, driven by a RMB 129.48 million gain on deemed disposal of a subsidiary. * Post-period, it signed TY-9591 China deals with Qilu, including about RMB 700 million upfront and a pending H-share subscription at HK$ 7.3. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287385), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)